Availability of appropriate HLA partially-matched and restricted tabelecleucel cell product
HLA-matched or partially matched (7/8 or 8/8) related or unrelated donor is available to donate
Must have two partially HLA-matched CBUs for part 1; and one partially HLA-matched CBU for part 2
Patients developing EBV lymphomas or lymphoproliferative disorders following an allogeneic organ transplant; in these cases, the lymphoma is usually of recipient origin; EBV-specific T-cells will be selected from the MSKCC bank expanded from an EBV-seropositive normal donor who is at least matched for 1) 2 HLA antigens and 2) one restricted allele with the EBV lymphoma; if the origin of the lymphoma is unknown, T-cells partially matched with the recipient transplant will be used, since these lymphomas are usually of host origin; using this approach to donor selection, it is expected that the EBV-specific, HLA restricted cytotoxic T-cells expanded from the HLA partially-matched donor would be able to recognize and kill lymphoma cells presenting EBV antigens in the context of an appropriate HLA restricting element; priority will be given to the use of partially matched EBV specific T cells known to be restricted by an HLA allele shared by the lymphoma (or, if known, the patient)
Partially matched related donors will be at least haploidentical (matched at >= 3 of 6 HLA A, B, DRB1 loci)
Matched sibling donor (HLA 8/8), if available, or a unrelated partially HLA matched single unit based on the following priority:\r\n* First (1st) priority: 4/6 matched unit, cell dose >= 5 x 10^7 nucleated cells/kg\r\n* Second (2nd) priority: 5/6 matched unit, cell dose >= 4 x 10^7 nucleated cells/kg\r\n* Third (3rd) priority: 6/6 matched unit, cell dose >= 3 x 10^7 nucleated cells/kg
DONOR: Donor must be related to patient and be partially (>= 3/6 antigen) HLA-matched
Patients must have a matched or partially matched UCB unit with >= 2.5 x10^7 nucleated cells/kg of recipient weight at the time of cryopreservation
Patients must have two partially HLA-matched CBUs
DONOR: Partially HLA matched family member
DONOR: donor must be related to patient and be partially (>= 3/6 antigen) HLA-matched
Patients must have one or two partially HLA-matched CBUs
DONOR: Partially HLA matched family member
Has a suitable partially human leukocyte antigen (HLA)-matched (>= 3 of 6) family member donor
Availability of appropriate partially HLA-matched and restricted tabelecleucel cell product
Has a suitable human leukocyte antigen (HLA) partially matched family member donor (HLA identical or phenotypically matched 8/8 family member donors will not be used on this protocol)
Eligible patients will have one of the following sources of donor stem cells:\r\n* Human leukocyte antigen (HLA) matched family member\r\n* Partially matched family member (mismatched for a single HLA locus at A, B, C or DR)\r\n* Fully HLA matched or partially mismatched unrelated marrow or peripheral blood stem cells (per institutional donor selection standards)\r\n* HLA matched or partially mismatched (at least 4/6 match at A, B, DR) cord blood
Eligible participants will only be transplanted for standard clinical indications, which include hematologic malignancies such as acute leukemia, high risk lymphoma, and multiple myeloma; much less commonly there are non-malignant indications for transplants; these include aplastic anemia and severe hemoglobinopathies; no patients will be transplanted for the primary purpose of HIV eradication; patients will undergo one of the following types of transplant:\r\n* Myeloablative, human leukocyte antigen (HLA) matched or partially HLA-mismatched (haploidentical), alloHSCT that includes high-dose post-transplantation cyclophosphamide (Cy)\r\n* Nonmyeloablative, HLA matched or partially HLA-mismatched, alloHSCT that includes high-dose post-transplantation Cy
RELATED DONOR: a 5/10, 6/10, 7/10, 8/10, 9/10 or 10/10 matched (or partially matched) family donor will be required for study entry; HLA typing can be performed at any time prior to conditioning and must be performed twice on both donor and recipient
Has a suitable single haplotype matched (>= 3 of 6) family member donor
DONOR: At least single haplotype matched (>= 3 of 6) family member
Has a suitable single haplotype matched (>= 3 of 6) family member donor
DONOR: At least single haplotype matched (>= 3 of 6) family member
Subject is a family member or employee of the investigator
Has a suitable single haplotype matched (>= 3 of 6) family member donor
DONOR: At least single haplotype matched (>= 3 of 6) family member
At least single haplotype matched (>= 3 of 6) family member
DONOR: At least single haplotype matched (>= 3 of 6) family member
Patient should be human leukocyte antigen (HLA) typed (A, B, C, DR and DQ) during induction therapy phase or a written explanation for not undergoing HLA typing on the flow sheet
Any human leukocyte antigen (HLA) type; (historic HLA typing is permitted)
Human leukocyte antigen (HLA)-A1, A2, A3, B35, or B51.
No suitable human leukocyte antigen (HLA)-identical sibling donor
Donor and recipient match each other for at least 7/8 human leukocyte antigen (HLA)-loci (HLA-A, B, C, and D-related [DR]).
Lack human leukocyte antigen (HLA)-identical related donor
Patients must have one related donor who is human leukocyte antigen (HLA) mismatched in the GVHD direction at two or more HLA loci
Available human leukocyte antigen (HLA)-haploidentical donor that meets the criteria
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping (blood test or buccal swab, historical documentation acceptable)
Patients must be human leukocyte antigen (HLA)-A2+
Human leukocyte antigen (HLA)-A2 positive based on flow cytometry
Absence anti-human leukocyte antigen (HLA) antibodies specific for HLA class I antigens expressed by the coagulation factor III (thromboplastin, tissue factor) (F3).cytosine deaminase (CD).carboxylesterase (CE) NSCs
Patients must be human leukocyte antigen (HLA)-DP4 positive
Patients must be human leukocyte antigen (HLA)-A*0201 positive
Leukocyte >= 3,000/ul
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping
Human leukocyte antigen (HLA)-A2 positive
Patients must have a related donor who is either human leukocyte antigen (HLA)-identical or a one antigen mismatch at the HLA- A; B; C; and DR loci
Patients must have human leukocyte antigen (HLA)-A2 phenotype
Human leukocyte antigen (HLA)-A1, -A2, -A3, or -A31 positive
Any human leukocyte antigen (HLA) type
Patient has anti-human leukocyte antigen (HLA) antibodies specific for HLA antigens expressed by the HB1.F3.CD NSCs
Patients must express human leukocyte antigen (HLA) -A1+, -A2+, or -A3+ (80% of patients)
DONOR: Human leukocyte antigen (HLA)-identical related donors or
DONOR: Human leukocyte antigen (HLA) identical to recipient subject
Human leukocyte antigen (HLA)-A*0201 (HLA-A2.1) positivity by molecular subtyping
Human leukocyte antigen (HLA)-A2 positive
Expression of human leukocyte antigen (HLA)-A:0201 or HLA-A:2402.
ELIGIBILITY FOR TREATMENT ON ARM 1: Patients must express human leukocyte antigen (HLA)-A*0201
Human leukocyte antigen (HLA)-A2-positive
Human leukocyte antigen HLA A2 positive
Expression of human leukocyte antigen (HLA)-A2
Patients must have one related donor who is human leukocyte antigen (HLA) mismatched in the GVHD direction at two or more HLA loci
Has a suitable human leukocyte antigen (HLA) haploidentical donor available
Human leukocyte antigen (HLA)-A2 positive by deoxyribonucleic acid (DNA) sequence analysis (by history or as part of this study); HLA testing can be done at local labs
Donor is blood-related and human leukocyte antigen (HLA)-haploidentical to the recipient
DONOR: Donors will be selected to minimize human leukocyte antigen (HLA) mismatch in the host-versus-graft direction
Patients must be human leukocyte antigen (HLA)-A*0201 positive
Available peptide-MHC pair that can be folded into a tetramer for which MCPyV TAg-specific cells can be generated and reactivity to cell lines expressing MCPyV TAg with the corresponding human leukocyte antigen (HLA)
Human leukocyte antigen (HLA)-A*02+ by serology by an ASHI accredited laboratory;
Leukocyte count <3000/µL,
Has a potentially suitable human leukocyte antigen (HLA) haploidentical donor available
Patients must be human leukocyte antigen (HLA) A2 positive by polymerase chain reaction (PCR) typing
Human leukocyte antigen (HLA) type A0201 or A2402
Patients must be human leukocyte antigen (HLA)-A*02:01-positive
Human leukocyte antigen (HLA)-A2 positive.
Any human leukocyte antigen (HLA) type (historic HLA typing is permitted)
Patients must be human leukocyte antigen (HLA)-A*0201 positive
Human leukocyte antigen (HLA)-A0201 or HLA-A2402
Availability of a willing and suitable human leukocyte antigen (HLA) identical related donor
Human leukocyte antigen (HLA)-identical sibling donor
Participants must be human leukocyte antigen (HLA)-A2 positive
Presence of human leukocyte antigen (HLA) antibodies
Availability of human leukocyte antigen (HLA)-identical sibling donor